Respirion Pharmaceuticals

About:

Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory diseases.

Website: https://respirionpharma.com/

Top Investors: Brandon Capital, Medical Research Future Fund (MRFF), Brandon BioCatalyst, Medical Research Commercialisation Fund (MRCF)

Description:

Founded in 2018, Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory disease. The Company is a spinout from the Telethon Kids Institute in Perth where the product development was incubated. Respirion’s lead product, an inhaled therapy for the life-threatening disease Cystic Fibrosis, has shown promising results in an early clinical study carried out with the Western Australian Department of Health. The Company has partnered with Australia’s largest life science investment fund, the Medical Research Commercialisation Fund, and the US Cystic Fibrosis Foundation to conduct further clinical trials in Australia and the US.

Total Funding Amount:

20M AUD

Headquarters Location:

Perth, Western Australia, Australia

Founded Date:

2018-01-01

Contact Email:

contact(AT)respirionpharma.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2024-05-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai